Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) recorded a 25% decline in attributable profit in the first quarter of 2026 to 83.9 million yuan from 112.1 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.
Earnings per share slipped to 0.12 yuan from 0.15 yuan in the corresponding period of the previous fiscal year.
The pharma firm's operating income slipped 0.3% to 2.42 billion yuan from 2.43 billion yuan in the year-ago period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments